- KR₩108bn
- KR₩461bn
- KR₩535bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.43 | ||
| Price to Tang. Book | 0.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.19 | ||
| EV to EBITDA | 13.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.74% | ||
| Return on Equity | -3.65% | ||
| Operating Margin | 1.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 517,641.07 | 543,759.15 | 522,741.08 | 507,358.33 | 535,137.86 | n/a | n/a | 1.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Handok Inc is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment mainly manufactures and sells prescription and over-the-counter drugs, including treatments for diabetes, hypertension, kidney diseases, respiratory diseases, central nervous system disorders, rare diseases, as well as anticancer drugs. The Medical Device segment mainly sells medical devices and diagnostic reagents. The Contract Manufacturing segment mainly provides contract manufacturing and quality control services for pharmaceuticals. The Real Estate Leasing segment mainly engages in the real estate leasing business.
Directors
- Yeong Jin Kim CHM (63)
- Jin Gi Baek CCE (62)
- Wu Yik Jang VPR (56)
- Byeong Ho Yoon VPR (61)
- Jang Sik Jung MDR (54)
- Du Seop Kim MDR (58)
- Hyeon Yik Kim MDR (51)
- Eul Jun Park MDR (53)
- Sin Gu Yeo MDR (54)
- Jong Yil Jung OTH (63)
- Min Bok Lee OTH (45)
- Yun Ju Lee OTH
- Jin Su Han NID (60)
- Seong Eun Yoo NID (63)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 1st, 1954
- Public Since
- June 30th, 1976
- No. of Shareholders
- 13,491
- No. of Employees
- 883
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 12,990,956
- Address
- 132, Teheran-ro, Gangnam-gu, SEOUL, 06235
- Web
- https://www.handok.co.kr/
- Phone
- +82 25275114
- Auditors
- KPMG Samjong Accounting Corp
Latest News for 002390
Upcoming Events for 002390
Q3 2026 Handok Inc Earnings Release
Q4 2026 Handok Inc Earnings Release
Handok Inc Annual Shareholders Meeting
Similar to 002390
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
As of Today at 21:02 UTC, shares in Handok are trading at KR₩8,320. This share price information is delayed by 15 minutes.
Shares in Handok last closed at KR₩8,320 and the price had moved by -28.28% over the past 365 days. In terms of relative price strength the Handok share price has underperformed the FTSE Developed Asia Pacific Index by -46.74% over the past year.
The overall consensus recommendation for Handok is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Handok dividend yield is 2.4% based on the trailing twelve month period.
Last year, Handok paid a total dividend of KR₩200, and it currently has a trailing dividend yield of 2.4%. We do not have any data on when Handok is to next pay dividends.
We do not have data on when Handok is to next pay dividends. The historic dividend yield on Handok shares is currently 2.4%.
To buy shares in Handok you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩8,320, shares in Handok had a market capitalisation of KR₩108bn.
Here are the trading details for Handok:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 002390
Based on an overall assessment of its quality, value and momentum Handok is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Handok is KR₩50,000. That is 500.96% above the last closing price of KR₩8,320.
Analysts covering Handok currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Handok. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.48%.
As of the last closing price of KR₩8,320, shares in Handok were trading -13.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Handok PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,320.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Handok's management team is headed by:
- Yeong Jin Kim - CHM
- Jin Gi Baek - CCE
- Wu Yik Jang - VPR
- Byeong Ho Yoon - VPR
- Jang Sik Jung - MDR
- Du Seop Kim - MDR
- Hyeon Yik Kim - MDR
- Eul Jun Park - MDR
- Sin Gu Yeo - MDR
- Jong Yil Jung - OTH
- Min Bok Lee - OTH
- Yun Ju Lee - OTH
- Jin Su Han - NID
- Seong Eun Yoo - NID